Navigation Links
Blood Test May Spot Pancreatic Cancer Early
Date:9/1/2009

Researchers hope to detect the disease while it is still treatable

TUESDAY, Sept. 1 (HealthDay News) -- Texas scientists say they have found small molecules in the blood that can spot pancreatic cancer, a finding that could have diagnostic implications in the future.

Levels of these molecules, called microRNAs, are elevated in patients suffering from pancreatic cancer, the fourth-leading cancer killer in the United States. The disease usually isn't diagnosed until it is in an advanced stage, when treatment is all but ineffective, the researchers say. Less than 5 percent of these patients survive five years past diagnosis.

"We have detected elevated levels of these microRNAs in the blood of pancreatic cancer patients," said lead researcher Subrata Sen, of the University of Texas M.D. Anderson Cancer Center's department of molecular pathology.

"This is an extremely promising finding in terms of developing a blood-based assay for detecting pancreatic cancer," he said.

If such a test could be developed, the question remains: Who should be screened? Sen thinks people with a family history of pancreatic cancer and those with risk factors for the disease, such as smoking, are the first candidates for testing.

However, how early high levels of these biomarkers appear in the development of pancreatic cancer is still unknown, Sen said. "That's the million-dollar question," he said. "That is something that has to be investigated with a bigger patient population."

MicroRNAs are short strands of RNA that regulate what proteins genes make, and they play an important role in both normal cells and cancerous cells. Changes in microRNAs have been seen in different cancers. Because microRNAs can be detected in blood, that may be useful in diagnosing cancer, Sen said.

The report was published in the Sept. 1 online edition of Cancer Prevention Research.

For the study, Sen's team looked at four microRNAs that have been linked to pancreatic cancer: miR-21, miR-210, miR-155 and miR-196a. The researchers looked at levels of these microRNAs in 28 patients with pancreatic cancer and compared them with 19 healthy individuals.

The team found the four biomarkers accurately detect pancreatic cancer 64 percent of the time. In addition, these biomarkers were able to find patients who did not have pancreatic cancer 89 percent of the time.

Toumy Guettouche, manager of the Oncogenomics Core Facility at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, thinks this test shows promise, but is far from being ready for "prime time."

"This is an interesting diagnostic method with a lot of potential," Guettouche said.

However, the sensitivity and specificity of the test is too low, he said. "This would have no chance of getting diagnostic clearance [from the FDA]," he added. It looks for 98 percent accuracy, he noted.

In addition, Guettouche said these same microRNAs have been linked with other cancers. "The problem is to determine pancreatic cancer to begin with," he said.

"What tells you that these upregulated microRNAs are from pancreatic cancer? They could be from another cancer," he said.

More information

For more information on pancreatic cancer, visit the American Cancer Society.



SOURCES: Subrata Sen, Ph.D., department of molecular pathology, University of Texas M.D. Anderson Cancer Center, Houston; Toumy Guettouche, Ph.D., manager, Oncogenomics Core Facility, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine; Sept. 1, 2009, Cancer Prevention Research, online


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Blood Thinner May Prevent Chemo-Related Clots
2. Reflux Drugs OK With Blood Thinners
3. This Guys Got Blood, and Heart -- At 320 and Counting, Al Fischer Sets Record for Blood Donations
4. Summit VetPharm Helps Veterinarians Protect Against Product Diversion, Counterfeiting and Shrinkage Using Vectra(R) Bloodhound(R) Technology
5. Omron Healthcare Reaches 100 Million Blood Pressure Monitor Units Sold
6. Steady Improvements Seen for Young Blood Cancer Patients
7. Memorial Blood Centers in Urgent Need of Type O Negative and Type B Negative Blood Donors
8. Blood Flow Mismatch Seen in Pancreatic Cancers
9. Mayo Clinic Proceedings: Common Blood Disorder May Not be Linked to as Many Serious Diseases, as Previously Thought
10. Cord Blood America $1.6 Million in Debt Retired in Third Quarter 2009
11. Blood Mercury Levels Rising Among U.S. Women
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Blood Test May Spot Pancreatic Cancer Early
(Date:10/13/2017)... , ... October 13, 2017 , ... “The Journey: From ... every danger possible to save lost souls in the Philippines. “The Journey: From the ... is a dedicated teacher of the Bible. She has taught all ages and currently ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... CITY, Fla. (PRWEB) , ... October 12, 2017 , ... ... cold therapy products, announced today the introduction of an innovative new design of the ... multipurpose pad so you get maximum comfort while controlling your pain while using cold ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... delivery system that we intend to develop to enable prevention of a major ... to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... for the 49th Congress of the International Society of Paediatric Oncology (SIOP) ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation announce a ... sensors for real-time monitoring of patients with trauma-related and ... focused on disruptive health solutions for rare disorders and ... record and integrate behavioral, cognitive, physiological and contextual data. ... ...
(Date:9/25/2017)... AMSTERDAM , Sept. 25, 2017   ... Trial Master File solutions, today—from the IQPC Trial ... Amsterdam , NL)—announced that EastHORN Clinical Services ... its clinical programs and TMF management. EastHORN, a ... Montrium,s eTMF platform to increase transparency to enable ...
(Date:9/22/2017)... ROCKVILLE, Md. , Sept. 22, 2017  As ... by Republican Senators Bill Cassidy (R-LA) and ... Kalorama Information notes that the medical device industry is ... the medical device tax, the 2.3% excise tax on ... Act.  But they also want covered patients, increased visits ...
Breaking Medicine Technology: